Key Highlights
- Radar Therapeutics raises $13.4 million in seed financing led by NfX Bio.
- Investors include Eli Lilly and Company, Biovision Ventures, and KdT Ventures.
- Funding to support advancement of internal programs, team expansion, and partnering.
- Developing programmable genetic and mRNA-based therapeutics with RNA sensors.
Source: Business Wire
Notable Quotes
- “With Radar’s technology, we can now precisely alter the biology of the cell, delete harmful cells, or potentially reprogram cells for autoimmune diseases. This has the potential to enable a new generation of safer, more durable, and effective mRNA therapeutics for applications beyond vaccines.” — Jim Collins, Ph.D., Co-Founder at Radar Therapeutics
- “Creating genetic expression-regulation systems that operate at the level of translation while being programmable to ensure compatibility with next-generation mRNA-based medicines has been a long-lived dream.” — Xiaojing Gao, Ph.D., Associate Professor of Chemical Engineering at Stanford and Radar Co-Founder
- “Like a safety switch, our payload is always off, and only gets turned on in the right cell. We can selectively write a function into any cell type. Programmable mRNA-based therapies have the potential to be in vivo, scalable, and modular, to improve patient access.” — Sophia Lugo, CEO & Co-Founder at Radar Therapeutics
SoHC's Take
Radar Therapeutics’ recent $13.4 million seed financing marks a significant milestone in the biotech industry, particularly in the realm of genetic and mRNA-based therapeutics. By leveraging innovative RNA sensor technology, Radar is positioned to transform the landscape of precision medicine, offering targeted, controlled, and safe therapeutic interventions. The support from prominent investors underscores the potential of Radar’s platform to address unmet medical needs and revolutionize treatments for a range of diseases. This advancement not only promises enhanced patient outcomes but also demonstrates a significant leap towards the practical application of sophisticated genetic therapies.
